Home/Pipeline/Lead ADC Program (Ovarian Cancer)

Lead ADC Program (Ovarian Cancer)

Ovarian Cancer

Pre-clinicalActive

Key Facts

Indication

Ovarian Cancer

Phase

Pre-clinical

Status

Active

Company

Medicovestor

About Medicovestor

Medicovestor is a private, preclinical-stage biotech developing a next-generation ADC platform designed to combine targeted cytotoxicity with potent immune system activation. The company is targeting pancreatic and ovarian cancers, two areas with high unmet medical need and notoriously difficult to treat. Its approach aims to improve upon current ADC therapies by engaging the immune system to create a more durable anti-tumor response. As a pre-revenue entity, its success hinges on validating its platform in the clinic and securing strategic partnerships or further funding.

View full company profile

Therapeutic Areas

Oncology Pancreatic Cancer Ovarian Cancer

Other Ovarian Cancer Drugs

Drug	Company	Phase	Status
EXO‑Ovarian Cancer Test	INOVIQ	Phase 2/3	Active
CAR‑iNK‑OvCa	Cartherics	Preclinical	Active
MagSense™ FR Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Yondelis (trabectedin)	PharmaMar	Approved	Commercial/Lifecycle
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
NP-G2-044 + Chemotherapy Agents	Novita Pharmaceuticals	Phase 2a	Active (combination strategy)
Ivospemin (SBP-101)	Panbela Therapeutics	Phase 2	Active
Ovarian Cancer Early Detection Assay	GenEndeavor	Pre-clinical	Active
INVAC-1	Invectys	Phase 2	Active
Folate Receptor-Targeted PCC	Indi Molecular	Preclinical	Active
Immunomodulator Platform	OmniCyte	Pre-clinical	Active
Platform Candidate	FLAG Therapeutics	Preclinical	Active